News
Company News: Cardior strengthens patent portfolio of miRNAs for the diagnosis and therapy of heart and kidney diseases
— Key patents acquired from Bayerische Patentallianz
Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has acquired a portfolio of four microRNA (miRNA) patents from Bayerische Patentallianz GmbH (BayPAT).
Company News: Heraeus Medical facilitates hospital-patient interaction with new digital solution
— HeraeusCare® digitizes pre- and post-operative patient care in orthopedic surgery
— Improved medical outcomes and significant cost savings
In order to streamline hospital-patient interactions in orthopedic surgery, Heraeus Medical provides a novel web-based digital solution. It includes a dashboard for hospitals and a mobile application for patients. The solution called HeraeusCare® will be introduced at this year´s German Congress of Orthopaedics and Traumatology (DKOU) in Berlin, Germany, from October 23 to 26, 2018. An onsite demo of the solution will be shown at Heraeus Medical´s conference booth (Hall 4.2, booth no. 74).
Company News: Curetis, Beijing Clear Biotech Expand Strategic Collaboration for Unyvero in Greater China
— Exclusive Unyvero A50 distribution agreement extended to eight years
— Significant further contractual minimum purchase commitments by Beijing Clear Biotech for additional contract years
— Good progress in regulatory process for gaining market access for Unyvero A50 in China
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has significantly expanded its strategic collaboration with Beijing Clear Biotech (BCB) for the exclusive distribution of the Unyvero A50 Platform and Unyvero A50 Application Cartridges in Greater China.
Company News: Curetis secures financing facility of up to EUR 20 million through the issuance of convertible notes
— Funding enables further acceleration of commercial expansion and R&D programs
— EUR 3.5 million of first tranche of EUR 5 million to be funded today
This announcement contains inside information within the meaning of Article 7(1) of the Market Abuse Regulation.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has secured up to EUR 20 million in growth capital through the issuance of convertible notes by Curetis N.V. with share subscription warrants, to YA II PN, Ltd, an investment fund managed by Yorkville Advisors Global LP, a U.S.-based management firm (the “Investor” or “Yorkville”). Read more…